R
Ratiotx
Specializing in the development of targeted radiotherapeutics for the treatment of cancer
About Ratiotx
Ratio Therapeutics is a discovery-stage biotechnology company focused on developing advanced radiotherapeutics for the treatment of metastatic cancers. Utilizing a suite of proprietary technologies licensed from Cornell University, the company aims to create best-in-class targeted radiopharmaceuticals. These innovative compounds feature a tunable structural motif that allows them to reversibly bind to albumin, enhancing their pharmacokinetics (PK), improving drug availability, tumor delivery, and tumor loading, while minimizing side effects commonly associated with other radiotherapies.
The company operates in the biotechnology and pharmaceutical markets, primarily serving cancer patients and collaborating with major pharmaceutical companies for clinical trials. Ratio Therapeutics employs a business model that includes research and development, intellectual property licensing, and strategic alliances. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.
The team at Ratio Therapeutics comprises experienced scientists and researchers with strong expertise and long-standing relationships with key opinion leaders (KOLs) in the field. The company holds robust intellectual property positions across multiple platform technologies and has set a target for two Investigational New Drug (IND) filings in early 2022.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 80
- Open positions
- 10
- Dealroom signal
- 57.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Radioisotope Therapeutics, Radiopharmaceuticals, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2023 | $50M | $200M | Undisclosed | ↗ |
| SERIES AOther financing | Feb 2023 | $20M | $80M | Kenan Turnacioğlu · Schusterman Family Investments · Duquesne Capital Management | ↗ |
Growth signals
Latest recorded traffic for Ratiotx is 6.1K monthly website visits, up 45.2% over the last three months. Ratiotx's team grew 11.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Schusterman Family Investments- DMDuquesne Capital Management
- KTKenan Turnacioğlu
Other known investors2 additional known investors
Cornell Tech
Cornell University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ratiotx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ratiotx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.